Anti-GP 2 (Glycoprotein 2) IgA ELISA Kit

Glycoprotein 2 (GP2) is a major protein expressed on the surface of pancreatic acinar cells and zymogen granules, and it plays a critical role in the innate immune system by binding to bacteria and facilitating their clearance. In the immune context, GP2 can elicit the production of specific IgA autoantibodies (GP2-IgA), which are detectable in blood and mucosal secretions. The presence of GP2-IgA reflects immune recognition of GP2 and is associated with dysregulated mucosal immunity and inflammatory processes, particularly in the gastrointestinal tract. As a biomarker, GP2-IgA provides insight into autoimmune and inflammatory activity targeting the pancreas and gut.

In research, GP2-IgA is studied as a biomarker for inflammatory bowel diseases (IBD), especially Crohn’s disease. Elevated GP2-IgA levels have been linked to disease activity, severity, and specific phenotypes such as ileal involvement. Researchers use GP2-IgA measurements to explore mechanisms of gut barrier dysfunction, mucosal immunity, and microbial interactions that contribute to chronic inflammation. Studies also investigate its predictive value for disease progression, relapse, or response to therapy, making it a valuable tool for understanding disease pathophysiology.

Clinically, GP2-IgA is increasingly recognized as a diagnostic and prognostic biomarker in IBD. Its detection helps differentiate Crohn’s disease from ulcerative colitis and may support early diagnosis in ambiguous cases. Additionally, GP2-IgA can be used to monitor disease activity and guide therapeutic decision-making, particularly in patients with ileal disease or those at higher risk of complications. Overall, GP2-IgA serves as a bridge between research into mucosal immune mechanisms and clinical management of autoimmune and inflammatory gastrointestinal disorders.

This product is manufactured in Germany by Medipan GmbH.